Careers  |  Sign In  |  Register

Investigating MET Exon 14 Mutations in Patients With NSCLC

Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights into a recent study, conducted in collaboration with Foundation Medicine, that looked at 60,000 patients with non-small cell lung cancer (NSCLC) with a subset of 1,387 patients with the MET exon 14 (METex14) mutations.

Learn more by clicking here.